Medicalcv Inc

Medicalcv — Investor Presentation (August 2007)

37 slides from Medicalcv's investor presentation, Aug 29, 2007

  1. Slide 1: Surgical Ablation Systems

    SURGICAL ABLATION SYSTEMS August 29, 2007

  2. Slide 2: Forward-Looking Statement Disclaimer

    This presentation contains certain forward-looking statements of expected future developments, as defined in the Private Securities Litigation Reform Act of 1995. The forward-looking statements in this presentation refer to expectations regarding our development and commercialization of surgical abl

  3. Slide 3: Company Profile & Recent Developments

    Company Profile & Recent Developments 2 Incorporated: In March 1992, as a Minnesota Corporation Redirected: In August 2004, newly repopulated management redirects company to new market Purpose: Fulfill unmet cardiovascular surgery needs Long Term Objective: Develop stand-alone, closed chest, beating

  4. Slide 4: Company Information

    Company Information 3 Company: MedicalCV, Inc. Market: OTC Bulletin Board Symbol: “MCVI” Recent Stock Price (1): $2.40 Market Cap (1): $23.6 million – 9.8 million Common Shares 14.0 million Fully-Diluted Shares (1) Based on the closing bid price on August 24, 2007.

  5. Slide 5: Investment Highlights

    Investment Highlights Experienced management team with strong track record of execution and demonstrated medical device success Treatment of Atrial Fibrillation is a large and growing market opportunity* Positioned to commercialize stand-alone soft tissue ablation procedure Broad patent portfolio Ho

  6. Slide 6: Market Overview

    Market Overview Atrial Fibrillation (AF) is an irregular heartbeat in which abnormal electrical impulses cause the upper chambers of the heart (atria) to fibrillate, or quiver, at rapid rates of 400 to 600 times per minute, resulting in an inefficient cardiac cycle, characterized by inadequate ventr

  7. Slide 7: AF Treatment Options

    AF Treatment Options Drugs (Palliative) Success rate 50% (1-yr), 40% (2-yrs) Catheter-Based* (Palliative/Curative) Success rate of 40% to 70% Surgical* (Curative) Open chest Maze Procedure Disassemble/Reassemble (Cut & Sew) Success rate of >90% MedicalCV’s stand-alone soft tissue ablation system** S

  8. Slide 8: Lone AF Opportunity

    Lone AF Opportunity AF Patients* 5,000,000 50% Asymptomatic** 2,500,000 50% Drug Responsive** 1,250,000 Stand-Alone Market Potential 1,250,000 *Miyasaki Y, et al. Secular Trends in Incidence of Atrial Fibrillation in Olmstead County, Minnesota, 1980 to 2000, and Implications on the Projections for F

  9. Slide 9: Reimbursement: Hospital & Physician

    Reimbursement: Hospital & Physician ’07 Hospital Reimbursement: Concomitant Ablation Primary Procedure Payment (DRG): ~$25,000 3-5 Day Stay Net Profit per Procedure: ~$5-10K No additional Reimbursement for: Ablation, Supplies, and OR Time ’07 Physician Reimbursement: Concomitant Ablation Primary Pro

  10. Slide 10: Market Growth: Stand Alone AF Treatments

    Market Growth: Stand Alone AF Treatments 1.25MM Non-Medication Responsive Patients EP Ablation Sub-Optimal and/or Non-Reproducible Clinical Results Negative Financial Impact on Hospitals Negative Financial Impact on Physicians Concomitant Ablation: 90% of Surgical Ablation Procedures Limited Growth:

  11. Slide 11: Surgical AF Ablation Market: HRi '07

    Surgical AF Ablation Market: HRi ’07* Assumption: 1.25MM Non-Medical AF Patients** Year Stand Alone Concomitant Total # Proc’s % Pt.’s # Proc’s % Pt.’s # Proc’s % Pt.’s 2005 1,143 0.09% 22,076 1.77% 23,219 1.86% 2006 1,884 0.15% 23,921 1.91% 25,805 2.06% 2007 3,140 0.25% 27,413 2.19% 30,553 2.44% 20

  12. Slide 12: Market Growth: Example Nissen Fundoplication

    Market Growth: Example Nissen Fundoplication Surgical Treatment for Chronic Heartburn 1990: 5000 Cases Maximally Invasive (Umbilicus to Sternum) 5-7 Day Hospital Stay 6-week Recovery Laparoscopic Nissen Fundoplication 1992: Technology Enables Laparoscopic Approach Adopted by Users with Excellent End

  13. Slide 13: Market Growth: Benchmark Lap. Nissen Fundoplication

    Market Growth: Benchmark Lap. Nissen Fundoplication Stand Alone Ablation Historical Growth Rate Conservative Growth Estimate Year # Proc’s % Pt’s Year # Proc’s % Pt’s 1992 7,500 0.20% 2005 1,000 0.08% 1993 15,000 0.39% 2006 1,500 0.12% 1994 25,000 0.66% 2007 2,500 0.20% 1995 40,000 1.05% 2008 4,000

  14. Slide 14: Surgical AF Ablation Market Estimate

    Surgical AF Ablation Market Estimate Assumption: 1.25MM Non-Medical AF Patients Year Stand Alone Concomitant Total # Proc’s % Pt.’s # Proc’s % Pt.’s # Proc’s % Pt.’s 2005 1,000 0.08% 22,076 1.77% 23,076 1.85% 2006 1,500 0.12% 23,921 1.91% 25,421 2.03% 2007 2,500 0.20% 27,413 2.19% 29,913 2.39% 2008

  15. Slide 15: Business Strategy

    Market ATRILAZE™ Surgical Ablation Wands* Concomitant Open Heart Procedures (CABG & VALVE) Closed Chest, Robotic/Endoscopic Beating Heart Procedures Ideal for Multiple Lesions Sets & Ganglionated Plexi Introduce SOLAR™ Surgical Ablation System** Expect it to be used as both a stand-alone product and

  16. Slide 16: MedicalCV's Laser Platform

    MedicalCV’s Laser Platform 1064nm Wavelength Focused, High Energy Transmission Minimal Energy Spread/Dispersion Optimized for Beating Heart Application on Atrial Tissue Sub-Millimeter Fiber Optic Narrow, Full Thickness Tissue Lesion (<3mm) Miniaturization of Delivery System Flexibility for Single-Si

  17. Slide 17: Epicardial Ablation (Endocardial View)

    Epicardial Ablation (Endocardial View) 16

  18. Slide 18: Histology: Atrial Appendage

    Histology: Atrial Appendage 17

  19. Slide 19: ATRILAZE: Generation 1

    510(k) Cleared for Cardiac Tissue Ablation 18 ATRILAZE™: Generation 1

  20. Slide 20: ATRILAZE: Generation 2

    19 ATRILAZE™: Generation 2 510(k) Cleared for Cardiac Tissue Ablation

  21. Slide 21: ATRILAZE Surgical Ablation System

    ATRILAZE™ Surgical Ablation System 20 510(k) Cleared for Cardiac Tissue Ablation

  22. Slide 22: ATRILAZE Clinical Experience to Date

    ATRILAZE™ Clinical Experience to Date 57 Concomitant Procedures to Date Northwestern University (Chicago, IL) Baylor Medical Center (Dallas, TX) Christus Santa Rosa (San Antonio, TX) Banner Heart Hospital (Mesa, AZ) Shea Scottsdale (Scottsdale, AZ) University of Michigan (Ann Arbor, MI) 7 Stand-Alon

  23. Slide 23: ATRILAZE Clinical Results to Date

    ATRILAZE™ Clinical Results to Date 16 Patient Study (Baylor Medical Center) Concomitant Procedures CABG, MVR, MVR/CABG, AVR, & ASD Ablation Procedure Time: 2-15 minutes Chronic AF: 6 Patients Paroxysmal AF: 10 Patients 30-Day Follow-Up 13/14 Free of AF 60-Day Follow-Up 9/10 Free of AF 6-Month Follow

  24. Slide 24: SOLAR Surgical Ablation System

    SOLAR™ Surgical Ablation System 510(k) Cleared for Soft Tissue Ablation 23

  25. Slide 25: Scientific Advisory Board

    Patrick M. McCarthy, MD (C) Northwestern University Lishan Aklog, MD Phoenix, AZ Antonio M. Calafiore, MD Catania, Italy Michael P. Caskey, MD Scottsdale, AZ Marc Gerdisch, MD Chicago, IL Baron L. Hamman, MD Baylor University Ralph Lazzara, MD University of Oklahoma Robert R. Lazzara, MD Tampa, FL Y

  26. Slide 26: SOLAR Surgical Ablation System

    Laser Controller Orbital Track 25 SOLAR™ Surgical Ablation System

  27. Slide 27: SOLAR System Animation

    SOLAR™ System Animation 510(k) for Soft Tissue Ablation Only; Minimally Invasive Cardiac Tissue Indication Requires Additional FDA Filing(s) 26

  28. Slide 28: Dr. Pat McCarthy: Concomitant PVI with MVR

    Dr. Pat McCarthy: Concomitant PVI with MVR Sternotomy Approach 27

  29. Slide 29: Dr. Michael Caskey: Concomitant PVI with MVR

    Right, Mini-Thoracotomy Approach Full Cox-Maze Dr. Michael Caskey: Concomitant PVI with MVR 1 2 3 4 28

  30. Slide 30: SOLAR Clinical Experience to Date

    SOLAR™ Clinical Experience to Date 6 Concomitant Procedures to Date Pat McCarthy, MD (Chicago, IL) (x2) Michael Caskey, MD (Scottsdale, AZ) Carmelo Otero, MD (San Antonio, TX) Steven Bolling (Ann Arbor, MI) Husam Balkhy (Milwaukee, WI) Box Lesion Created on Beating Heart Additional Lesion Sets of Fu

  31. Slide 31: SOLAR System Animation

    SOLAR™ System Animation 30 510(k) for Soft Tissue Ablation Only; Minimally Invasive Cardiac Tissue Indication Requires Additional FDA Filing(s)

  32. Slide 32: SOLAR System Launch Strategy

    SOLAR™ System Launch Strategy Commence Controlled Launch Focus on 4 High Volume Markets Focus on 6 Large Volume Hospitals “Go Deep” vs. “Go Wide” penetration strategy Estimated Pricing at Full Commercialization Disposable Component: $5-7.5K (Years 1 - 5) Capital Components: Capital Recovery Charge (

  33. Slide 33: MedicalCV Intellectual Property Portfolio

    MedicalCV Intellectual Property Portfolio 32 6 Issued US Patents #7,137,977: Atraumatic Laser Tip for AF Treatment #7,163,534: Laser-Based Maze Procedure for AF #7,169,142: Malleable Energy Wand for Maze Procedure #7,232,437: Transmurality Testing #7,238,179: Guided Ablation with Visualization #7,23

  34. Slide 34: Competition

    Competition Technology Weaknesses Companies Strengths Radiofrequency Established Technology (RF Energy) Established Customer Base Good Concomitant Results Easy & Fast to Use No True Minimally Invasive System Existing System Requires 3-5 Day Length of Stay & Bilateral Thoracotomy Microwave Can be use

  35. Slide 35: Balance Sheets

    Balance Sheets FY07 ended 4/30/07 $11.0M cash used in operations, acquisition of PPE, and building lease payments $8.0M 11% secured debt financing in April 2007 Warrant for the purchase of 1,200,000 shares issued at closing plus additional interest accrual warrants to be issued during 3-year term of

  36. Slide 36: Fully Diluted Capitalization

    Fully Diluted Capitalization (as of 7/2/07) # Outstanding Avg. Exercise Price Common Stock 9,839,724 Warrants 3,175,349 $5.41 Options 953,809 $8.51 13,968,882 Market capitalization of $23.6M as of August 24, 2007 ($2.40 closing bid price) As of July 2, 2007: Warrants for the purchase of 2,094,565 sh

  37. Slide 37: Statements of Operations

    Statements of Operations FY07 ended 4/30/07 ATRILAZE single-use device sales of $31,500 S&M increased due to preparing for launch of SOLAR System (headcount, marketing, etc.) G&A in FY07 included $1.3M of SFAS 123R non-cash share-based compensation R&D increased due to development of SOLAR System, s

Medicalcv — Investor Presentation (August 2007) on 6ix